

Declaration of the End of Trial Form (cf. Section 4.2.1 of the *Detailed guidance on the request to the competent authorities for authorisation of a clinical trial on a medicinal product for human use, the notification of substantial amendments and the declaration of the end of the trial*¹)

NOTIFICATION OF THE END OF A CLINICAL TRIAL OF A MEDICINE FOR HUMAN USE TO THE COMPETENT AUTHORITY AND THE ETHICS COMMITTEE

For official use

Date of receipt :	Competent authority registration number : Ethics committee registration number:
-------------------	--

To be filled in by the applicant

A MEMBER STATE IN WHICH THE DECLARATION IS BEING MADE: the Netherlands

B TRIAL IDENTIFICATION

B.1 EudraCT number: 2018-001406-29
B.2 Sponsor's protocol code number: GLPG1690-CL-304
B.3 Full title of the trial: A Phase 3, randomized, double-blind, parallel-group, placebo-controlled multicenter study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis

C APPLICANT IDENTIFICATION (please tick the appropriate box)

C.1 DECLARATION FOR THE COMPETENT AUTHORITY	<input checked="" type="checkbox"/>
C.1.1 Sponsor	<input type="checkbox"/>
C.1.2 Legal representative of the sponsor	<input type="checkbox"/>
C.1.3 Person or organisation authorised by the sponsor to make the application.	<input checked="" type="checkbox"/>
C.1.4 Complete below:	
C.1.4.1 Organisation: PPD Netherlands BV	
C.1.4.2 Name : 5.1.2.e	
C.1.4.3 Address : Bornweg 12c, 6721 AH Bennekom, the Netherlands	
C.1.4.4 Telephone number : +31 318 655.1.2.e	
C.1.4.5 Fax number : +31 318 655.1.2.e	
C.1.4.6 E-mail : 5.1.2.e@ppdi.com	

C.2 DECLARATION FOR THE ETHICS COMMITTEE	<input type="checkbox"/>
C.2.1 Sponsor	<input type="checkbox"/>
C.2.2 Legal representative of the sponsor	<input type="checkbox"/>
C.2.3 Person or organisation authorised by the sponsor to make the application.	<input type="checkbox"/>
C.2.4 Investigator in charge of the application if applicable ² :	
• Co-ordinating investigator (for multicentre trial):	<input type="checkbox"/>
• Principal investigator (for single centre trial):	<input type="checkbox"/>
C.2.5 Complete below :	
C.2.5.1 Organisation:	
C.2.5.2 Name :	
C.2.5.3 Address :	
C.2.5.4 Telephone number :	
C.2.5.5 Fax number :	
C.2.5.6 E-mail :	

¹ OJ, C82, 30.3.2010, p. 1; hereinafter referred to as 'detailed guidance CT-1'.

² According to national legislation.

D END OF TRIAL

D.1 Date of the end of the trial in this Member State ? ³	yes <input type="checkbox"/> no <input checked="" type="checkbox"/>
D.1.1. (YYYY/MM/DD):	

D.2 Date of the end of the complete trial in all countries concerned by the trial ? ³	yes <input type="checkbox"/> no <input checked="" type="checkbox"/>
D.2.1 (YYYY/MM/DD):	

D.3 Is it an early termination ? ⁴	yes <input checked="" type="checkbox"/> no <input type="checkbox"/>
D.3.1 If yes, give date (2021/02/10):	
D.3.2 Briefly describe in an annex (free text):	
D.3.2.1 The justification for early termination of the trial; The decision to terminate this trial is based on recommendations of the Independent Data Monitoring Committee (IDMC) made on 09-Feb-2021, which was the 6 th unblinded review for the two phase 3 trials under the ziritaxestat program. Following this regular review of unblinded data, the IDMC concluded that: - There was a safety concern identified with 600 mg - There was a lack of efficacy signal in all arms of the study The IDMC's conclusion is that ziritaxestat's benefit-risk profile no longer supports continuing the phase 3 studies.	
D.3.2.2 Number of patients still receiving treatment at time of early termination in the MS concerned by the declaration and their proposed management: 46 patients need to be discontinued from the study immediately. For the randomized patients an End of Study Treatment (EOST) visit needs to be organized as soon as possible and a safety follow-up performed within a month after IMP discontinuation.	
D.3.2.3 The consequences of early termination for the evaluation of the results and for overall risk benefit assessment of the investigational medicinal product. Following the IDMC recommendations all clinical trials within the ziritaxestat development program will be discontinued.	

E SIGNATURE OF THE APPLICANT IN THE MEMBER STATE

E.1	I hereby confirm on behalf of the sponsor that: <ul style="list-style-type: none">• The above information given on this declaration is correct; and• That the clinical trial summary report will be submitted within the applicable deadlines in accordance with the applicable guidance by the Commission.⁵
------------	--

E.2 APPLICANT TO THE COMPETENT AUTHORITY (as stated in C.1)	<input checked="" type="checkbox"/>
E.2.1 Date :	
E.2.2 Signature :	
E.2.3 Print name:	5.1.2.e

³ In case of a multi-country trial, if the national and global end of trial dates are different in a given Member State, the sponsor shall submit this form two times :

1) At the end of the trial in the individual Member State, section D1.1. shall be completed and submitted to the respective National Competent Authority.

2) At the global end of the trial, the sponsor shall complete section D.2.1. with the global trial end date and the completed form shall be submitted to all participating Member States in order to allow the sponsor to prepare the trial result summary within the 12-months (or 6-months in case of paediatric trials) timeframe.

If the national and global end dates coincide in a concerned Member State, the form shall be submitted only once to the National Competent Authority of this Member State with both sections D1.1. and D2.1 complete.

⁴ Cf. Section 4.2. of the detailed guidance CT-1.

⁵ Section 4.3. of the detailed guidance CT-1.

E.3	APPLICANT TO THE ETHICS COMMITTEE (as stated in C.2) :	<input type="checkbox"/>
E.3.1	Date :	
E.3.2	Signature :	
E.3.3	Print name:	